Boule Diagnostics AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020
February 03, 2021 at 09:00 am EST
Share
Boule Diagnostics AB publ announced earnings results for the fourth quarter ended December 31, 2020. For the fourth quarter, the company announced sales was SEK 92.7 million compared to SEK 129.3 million a year ago. Operating loss was SEK 41.6 million compared to operating Income of SEK 15.1 million a year ago. Net loss was SEK 32.6 million compared to net income of SEK 7.2 million a year ago. Basic loss per share from continuing operations was SEK 1.68 compared to basic earnings per share from continuing operations of SEK 0.37 a year ago.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
